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Introduction
Bile acids are produced from cholesterol catabolism in the liver. Their amphipathic character allows for a pivotal role of bile acids in the emulsification and subsequent absorption of dietary fats, fat soluble drugs and vitamins from the small intestine. Bile acids are also recognized as potent signaling molecules with an important role in glucose, lipid and energy metabolism. Many bile acid signaling-effects are mediated via activation of the nuclear receptor Farnesoid X Receptor (NR1H4 or FXR) and G protein-coupled bile acid receptor-1 (Gpbar1 or TGR5). Bile acids themselves, modulators of bile acid transport and (semi)synthetic bile acid receptor agonists are therefore emerging as potentially useful therapeutic agents for a wide-spectrum of diseases. This review will discuss in detail the use of bile acid signaling in health and disease.
Bile acid synthesis and the enterohepatic circulation
In humans, the two major primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA) are synthesized in the liver, a process that involves at least 17 enzymes, which modify the cholesterol steroid rings, cleave side chains and eventually conjugate the acidic tail of the formed bile acid with taurine or glycine [1] . Bile acids can be synthesized via two different pathways. The classic, or neutral, bile acid pathway produces about 90% of bile acids in humans and is dependent on CYP7A1, the enzyme that converts cholesterol to 7α-hydroxycholesterol, which is subsequently converted to CDCA or CA. In the alternative, or acidic, pathway cholesterol is oxidized by CYP27A1 prior to hydroxylation by the enzyme CYP7B1, eventually generating CDCA [2] . In mice Cyp2c70 catalyzes the formation of muricholates, hydrophilic bile acids not present in humans [3] . The newly synthesized bile acids are conjugated to taurine or glycine for secretion into bile. Conjugation lowers the pKa and increases solubility and consequently bile acids can no longer passively pass cell membranes. In humans the ratio of glycine to taurine conjugation is about 3 to 1, while in rodents > 95% of bile acids are taurine conjugated.
Conjugated bile acids are actively secreted by hepatocytes into the canalicular space via the bile salt export pump (ABCB11 or BSEP) [4] , starting the process of bile formation. Bile salts are the most prevalent solutes in bile, but it also contains free cholesterol and phospholipids, secreted via the ABCG5/ABCG8 and multidrug resistance protein 3 (ABCB4 or MDR3; MDR2 in mice) transporters respectively [5, 6] . The mixed micelles formed by phospholipids and bile acids greatly reduce detergent effects of bile acids on cholangiocytes and allow for biliary cholesterol secretion. The solubilization of cholesterol by the mixed micelles prevents cholesterol crystallization and the formation of gallstones [7] . Newly formed bile is stored in the gallbladder from which it is secreted into the small intestine to facilitate digestion and the absorption of nutrients. Ingestion of a meal, and especially lipids passing the duodenum, induce the secretion of cholecystokinin (CCK) into the circulation. CCK stimulates gallbladder contraction and relaxation of the sphincter of Oddi, resulting in the expulsion of bile into the duodenum. As bile acids make their way through the digestive tract, up to 95% of bile acids are reabsorbed in the ileum, via the apical sodium dependent bile acid transporter (SLC10A2 or ASBT) located on the luminal, apical, side of the enterocytes [8] . In the enterocytes bile acids are bound by the intestinal bile acid binding protein (FABP6 or IBABP) and shuttled to the basolateral side of the cell where they are released into the portal circulation through the organic solute transporter complex (SLC51A/B or OSTαβ) [9] . Via the portal vein bile acids return to the liver, where the vast majority is taken up at the basolateral site of hepatocytes by the sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP) and by members of the organic anion transporting polypeptide (SLCO or OATP) family [8, [10] [11] [12] . Once bile acids are excreted into the biliary tree again, one loop of the enterohepatic cycle is completed. In humans bile acids are recycled about 6-10 times a day, and less than 10% of the total bile acid pool of 2-4 g is lost via the feces [8] . This loss is compensated by de novo synthesis of bile acids. In humans bile acids that escape reabsorption in the small intestine end up in the colon where they are deconjugated and dehydroxylated by bacteria forming the secondary bile acids lithocholic acid (LCA) and deoxycholic acid (DCA) from CDCA and CA respectively [13] . In mice, the primary bile acid β-muricholic acid (β-MCA) is converted by intestinal bacteria into ω-MCA and hyeodeoxycholic acid (HDCA) [14] .
As stated, hepatic reuptake of bile acids is very efficient, but not complete. This results in low levels of bile acids in the systemic circulation (2-10 µM), in sharp contrast to the higher concentrations (10-80 µM) in portal blood [15] . The amount and species of bile acids present in both the systemic and portal circulation is dynamic and follows a meal-dependent and circadian rhythm [16, 17] , which greatly influences bile acid receptor activation.
Bile acid receptors and their role in the regulation of bile acid homeostasis
As bile acids serve many different functions bile acid synthesis is inherently tightly regulated. The main regulators controlling bile acid synthesis are bile acids themselves, through efficient feedback regulation involving bile acid responsive receptors (Fig. 1) .
The cellular location of the two major bile acid receptors FXR and TGR5, in the nucleus or on the plasma membrane respectively, affects their exposure to different bile acids [18, 19] . CDCA is the most potent activator of FXR followed by DCA, LCA and CA, while TGR5 is highly responsive to conjugated bile acids, with TLCA and TDCA being the most potent agonists. It may not be surprising that both receptors are highly expressed in organs involved in the enterohepatic circulation, but also the immune system, adipose tissue and skeletal muscle are responsive to bile acids [19] .
The nuclear transcription factor FXR was the first bile acid receptor discovered [20, 21] and can both activate and repress gene transcription [22] . Of note, FXR has four splice variants that respond differently to stimulation by bile acids or agonists [23] . With regards to bile acid metabolism FXR serves as an important feedback regulator [24] . In the liver, activation of FXR leads to the transcription of another nuclear receptor, small heterodimer partner (NR1H2 or SHP) [25] . SHP subsequently inhibits the activity of hepatocyte nuclear factor 4 (NR2A1 or HNF4) and liver-related homologue-1 (NR5A2 or LRH1) [26] , resulting in inhibited expression of CYP7A1 and CYP8B1 and thus limiting bile acid synthesis [24] . Although FXR deficiency results in upregulated bile acid synthesis and an increased total bile acid pool [24] , in SHP deficient mice bile acid synthesis can still be inhibited [27] , indicating that other factors are also involved in bile acid feedback regulation. The recent report describing that FXR promotes posttranscriptional degradation of Cyp7a1 mRNA via induction of the RNA binding protein ZFP36L1 underscores that feedback regulation of FXR on bile acid synthesis occurs via multiple pathways [28] . Besides repressing bile acid synthesis, FXR activation also inhibits expression of the basolateral bile acid uptake transporter NTCP, limiting bile acid influx into the hepatocytes, whilst at the same time upregulating the expression of BSEP and ABCB4 stimulating bile acid and phospholipid efflux [29, 30] . This fine-tuning of the bile acid load in hepatocytes serves as an important protective mechanism against bile acid overload in cholestasis. A recent report on FXR mutations in humans emphasizes the pivotal role of FXR in the liver, as it was shown that complete loss of FXR function leads to very severe cholestasis and liver failure in neonatal patients [31] . This also highlights differences between mice and man, since FXR knockout (KO) mice have neither cholestasis nor liver failure.
In the enterocyte, FXR activation downregulates ASBT and upregulates IBABP and OSTαβ, limiting bile acid uptake from the intestine and increasing bile acid efflux into the portal circulation [32, 33] . Intestinal FXR activation also instigates the production of the hormone fibroblast growth factor 19 (FGF19, FGF15 in mice), which travels via the portal circulation to the hepatocytes and activates the Fibroblast Growth Factor Receptor 4 (FGFR4)/β-Klotho complex to reduce bile acid synthesis via Cyp7a1 and Cyp8b1 repression [34] .
In contrast to the extensive knowledge about the role of FXR activation in bile acid regulation, TGR5 has apparently no clear regulatory role in bile acid synthesis or homeostasis. Although TGR5-deficient mice have higher expression of CYP7A1, CYP8B1, NTCP and BSEP [35, 36] , they have similar serum bile acid levels and even a decreased total bile acid pool compared to wild type animals [35] .
Metabolic regulation by bile acid receptor signaling
Both FXR and TGR5 are essential regulators in the metabolic system. FXR is involved in lipid, glucose and amino acid metabolism, whereas TGR5 is an important player in energy expenditure, glucose balance, and the immune system. Animal studies and especially knock out mice models have contributed largely to our current understanding of the physiological impact of bile acid signaling on metabolic regulation.
FXR
FXR-deficient mice have increased hepatic lipid content as well as increased plasma cholesterol and triglycerides [24] . Conversely, activation of FXR by bile acids or the synthetic agonist GW4064 reduces steatosis as well as plasma triglycerides [37, 38] . SHP-mediated inhibition of fatty acid synthesis, via inhibition of steroid response element binding protein-1c (SREBP-1c) is likely to contribute to a lower triglyceride load in hepatocytes [37] . Additionally, activation of FXR increases liver ApoCII gene transcription, a lipoprotein lipase activator, while it decreases that of ApoCIII, a lipoprotein lipase inhibitor, resulting in increased lipolysis of triglycerides in the vasculature [39, 40] . FXR signaling has also been shown to affect cholesterol fluxes by stimulating reverse cholesterol transport and by promoting trans-intestinal cholesterol excretion (TICE) via changes in the hydrophobicity of the bile acid pool [41, 42] .
FXR has also been shown to regulate amino acid metabolism. It was demonstrated that FXR activation with the compound INT-747 stimulated catabolism of amino acids in primary hepatocytes. Additionally FXR activation by INT-747 stimulates the clearance of ammonium through induction of ureagenesis and glutamine synthesis, shown in vivo [43] .
In addition to its regulatory role on lipid homeostasis and amino acid metabolism FXR also has profound effects on glucose homeostasis. FXR-deficient mice exhibited higher serum glucose levels and impaired glucose and insulin tolerance, whilst FXR overexpression or stimulation by cholate feeding or administration of the compound GW4064 reduced hepatic gluconeogenesis and improved insulin sensitivity [38, 44] . In contrast, it was also reported that in the context of diet-induced obesity FXR deficiency was actually protective. This effect was not mediated via the loss of FXR in the liver, as liver-specific FXR KO mice were not protected against diet-induced obesity and display disturbed glucose homeostasis [45] . Further dissection of the role of tissue-specific FXR signaling regarding glucose regulation has provided more ambiguous results. For instance, hepatic loss of both FXR and its downstream target SHP actually improved lipid and glucose homeostasis in aged mice [46] . These findings were attributed to an increase in autophagic gene expression, which is normally repressed by FXR in the post-prandial phase [46, 47] . Intestinal FXR signaling also has provided contrasting results with respect to glycemic control. First of all, mice with selective genetic deletion of FXR in the intestine were protected against dietinduced obesity and diabetes [48, 49] . The inhibitory effect of the FXR agonist GW4064 on GLP-1 secretion [50] , an incretin hormone secreted by the intestinal L-cell which improves glycemic control and promote weight loss, may explain why loss of FXR signaling in the intestine improves glucose tolerance. In contrast, treatment with the intestine specific FXR agonist fexaramine, also improved obesity and diabetes in mice and stimulated browning of white adipocytes [51] . Mechanistically, fexaramine increases FGF15 signaling thereby altering the bile acid pool, ultimately increasing the level of the bile acid TLCA [52] . TLCA is a strong TGR5 agonist and induces TGR5-mediated GLP-1 secretion by the intestinal L-cell improving glucose tolerance and insulin resistance. Indeed, TGR5 was required to mediate the effects of fexaramine on weight gain and insulin resistance. Fexaramine treatment also increased energy expenditure [51] , an effect also strongly linked to TGR5 activation [53] . However, increased energy expenditure upon fexaramine treatment was still present in TGR5-deficient mice [51] indicating that another mechanism is also at play.
Several regulatory effects of FXR on glucose and lipid regulation are indirectly mediated via FGF15/19. Studies in FGF15-deficient mice showed that Fgf15 is required to maintain glucose levels and stimulate hepatic glycogenesis [54] . Furthermore, it was demonstrated that FGF19 inhibits gluconeogenesis via a CREB-PGC1α pathway [55] . In addition, administration of FGF19 in mice protects against diet-induced obesity by stimulating enhanced energy expenditure, which was suggested to be caused by repression of acetyl-CoA carboxylase 2 (ACC2). The reduction in ACC2 decreases mitochondrial Malonyl-CoA levels resulting in upregulation of Carnitine palmitoyltransferase I (CPT1) increasing the availability of fatty acids for oxidation [56, 57] . Moreover, FGF19 inhibits hepatic fatty acid synthesis by suppressing SREBP1c activity [58] . It is important to state that the supraphysiological doses of FGF19 used, combined with the mismatch between the human hormone and the murine FGF-receptors, warrant careful interpretation of the performed studies, especially when translating results towards clinical application [59] . Nevertheless, these studies do indicate that the effects of FGF15/19 signaling extend beyond the control of bile salt synthesis.
TGR5
TGR5 is an important player in energy expenditure, glucose balance, and the immune system [19] . In brown adipocytes and skeletal muscle, TGR5 stimulation activates thyroid hormone deiodinase 2 which converts inactive thyroxine (T4) into active 3,5,3′-triiodothyronine (T3) and stimulates energy expenditure [60] . Furthermore, TGR5 activation by the synthetic agonist INT-777 in adipose tissue stimulates mitochondrial biogenesis and mitochondrial fission, thus increasing overall adipocyte mitochondrial content and consequentially the capacity for mitochondrial (uncoupled) respiration [53] . Moreover, TGR5 activation by INT-777 induces beiging of white adipocytes mice [53] . The important role of TGR5 in energy homeostasis is reflected by the increased body weight and fat accumulation in TGR5 KO mice fed a high fat diet [35] , while treatment with the TGR5 agonist INT-777 results in the attenuation of obesity and diabetes in mice [61] . Protection against insulin resistance has largely been attributed to TGR5-mediated increased GLP-1 secretion from the intestinal L-cells [61, 62] and pancreatic β-cells [63] .
Additionally, TGR5 activation in immune cells, such as macrophages, has powerful immunosuppressive effects. Mechanistically, TGR5 reduces pro-inflammatory cytokine expression by inhibiting nuclear translocation of NFκB in a cAMP-PKA dependent manner [64] [65] [66] . Furthermore, TGR5-activation with INT-777 directly inhibits the inflammasome, a major driver of atherosclerosis development, by PKA mediated ubiquitination of NLRP3 [67] . Extracellular bile acids can dampen inflammation via TGR5, but accumulation of bile acids inside hepatocytes has been demonstrated to stimulate inflammation [68] . It has also been reported that bile acids can activate the inflammasome in macrophages, which is in contrast to the effects of TGR5 signaling [69] . A possible explanation for this discrepancy is the fact that the stimulatory effects of bile salts on the inflammasome were present when unconjugated DCA was applied in supraphysiological concentrations. DCA can enter cells via passive diffusion, as opposed to conjugated bile salts, which stay outside of the cell and can activate the TGR5 receptor. The relevance of TGR5 as a regulator of inflammation was demonstrated in vivo by increased sepsis and pro-inflammatory cytokine release in TGR5-deficient mice challenged with lipopolysaccharide (LPS) [67, 70] . Additionally, the immunomodulatory effects of TGR5 activation have beneficial effects on insulin resistance via modulation of the inflammasome and the mTOR pathway [67, 71] .
Besides the direct effects of TGR5 on immune cells, endothelial cells also express TGR5 and thereby contribute to anti-inflammatory effects of TGR5. TGR5 activation in endothelial cells has been shown to promote nitric oxide (NO) production, through phosphorylation of endothelial nitric oxide synthase (eNOS) [72] . In turn, the increase in NO results in reduced expression of adhesion molecules, limiting leukocyte extravasation [73] .
Bile acid receptor signaling as treatment for disease
The many processes regulated by FXR and TGR5 make them interesting therapeutic targets for a variety of diseases (Figs. 2 and 3), especially metabolic diseases and cholestasis. Indeed multiple drugs have been developed that target FXR or TGR5, or sometimes both, either systemically or in a tissue-specific manner. These drugs stimulate the regulatory effects of bile salt signaling on metabolism beyond their physiological role and are now being evaluated for clinical efficacy. In addition, therapies aimed at manipulating the enterohepatic circulation of bile salts are progressing in clinical trials. Here, the current clinical trials and preclinical studies evaluating the effects of pharmacological FXR and TGR5 agonists, bile acid transport inhibitors and FGF19-based therapies will be discussed.
Cholestasis
Therapeutic options for cholestatic diseases are scarce and treatment options are limited. With the current knowledge of the processes that contribute to the development of cholestatic liver injury new therapeutic strategies have been proposed in the form of FXR agonists, FGF19 mimetics and compounds that interrupt enterohepatic cycling of bile salts.
Targeting the FXR-FGF19 pathway
Cholestasis is characterized by hampered or abrogated bile flow and can have many different causes. After obstruction of bile flow the intrahepatic accumulation of bile salts and toxic biliary components are important contributors to the development of cholestatic liver injury [74] . Intrahepatic activation of FXR by bile salts will reduce the bile salt load on hepatocytes by limiting expression of bile salt uptake transporters, reducing bile salt synthesis and stimulating bile salt excretion. However, these intrinsic protective mechanisms are not sufficient to prevent cholestatic liver injury. Pharmacological activation of FXR with synthetic agonists can reduce bile acid synthesis and hepatic bile salt load to a greater extent, thereby limiting cholestatic liver injury. This mechanism of action was demonstrated in animal models of cholestasis, in which the bile acid derivative and FXR agonist obeticholic acid (OCA, also called INT-747 or 6-ECDCA) successfully reduced cholestatic liver injury [75, 76] .
Currently, OCA is the first synthetic FXR agonist that has been tested in clinical trials for the treatment of cholestasis [75] , specifically for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Both diseases are rare causes of cholestasis that are characterized by inflammation and destruction of the intrahepatic (both PBC and PSC) and extrahepatic (only PSC) bile ducts. In PBC patients, OCA reduced alkaline phosphatase (ALP) levels, a surrogate biomarker for progression of cholestatic liver disease, by at least 15% in approximately 50% of patients. On average a stable ALP level was reached at 1.67x the upper limit of normal [77] and OCA has been approved for the use in PBC patients. OCA is also being tested in PSC patients and the first results indicate reductions in plasma ALP levels (NCT02177136). Despite the promise of OCA for PBC and PSC, long term outcome parameters, such as liver transplant free survival, have not been evaluated yet and there are several concerns regarding its use that remain to be addressed. First of all, OCA caused pruritus in a dose-dependent manner resulting in treatment withdrawal for a small number of patients [77, 78] . For patients with cholestasis this is worrying as they already suffer from pruritus, and the prospect of increased pruritus may prevent them from taking the drug or limit their therapy adherence. A second concern is the decrease in high density lipoprotein (HDL)-cholesterol and increase in low density lipoprotein (LDL)-cholesterol upon OCA treatment [77, 78] . It is suggested that hepatic uptake from HDLcholesterol is increased due to FXR-stimulated expression of the scavenger receptor B1 [79] . Furthermore, increased levels of cholesteryl ester transfer protein (CETP) in hepatocytes and macrophages, induced by FXR activation, likely contributed to the shift towards a more unfavorable cholesterol composition [80] . Mice studies did not give cause to expect such changes in plasma cholesterol since mice do not express the CETP protein. Long term implications of these findings remain unclear. Thirdly, OCA activates FXR systemically, resulting in increased FGF19 levels due to intestinal FXR activation [77] . Although FGF19 further reduces bile acid synthesis, which is beneficial in cholestatic patients, it also has a proliferative effect on hepatocytes [81] . Both FGF19 and its hepatocyte receptor FGFR4 have been linked to hepatocellular carcinoma (HCC) [82] . The tumorigenic potential of FGF19 was demonstrated in mice by ectopic overexpression of FGF19 in the skeletal muscle, which lead to the development of liver tumors [83] . Whether the more modest OCA-induced FGF19 elevations also enhance tumor risk is unknown, warranting careful monitoring of patients receiving OCA, especially in PSC patients which already have an increased predisposition for tumor development [84] . Besides OCA, two other FXR agonists, GS-9674 (NCT02943460 and NCT02943447) and LJN452 (NCT02516605), are in phase II clinical trials to investigate effectiveness in cholestatic disorders. These components are not derived from bile acids and as such are transported and metabolized differently than OCA. For this reason it will be interesting to compare efficacy and side effects of these compounds with OCA.
The potential of FGF19 to reduce bile acid synthesis in PBC and PSC patients was further explored after the development of FGF19 mimetics, which lack the mitogenic potential of FGF19. One such mimetic is NGM282 (formerly called M70) which was designed in such a way that it selectively affects bile salt synthesis but does not stimulate proliferation of hepatocytes [85] . NGM282 was shown to prevent cholestatic liver injury in a murine model of cholestasis [86] and at present it is being tested in phase 2 clinical trials for both PBC and PSC patients. The first report mentioned that NGM282 treatment successfully decreased bile acid synthesis and reduced ALP by 15% in 48% of PBC patients [87] . Unexpected side effects of diarrhea and nausea were reported for 25% and 12.5% of patients receiving the dose of 3 mg of NGM282 in the trials. These side effects were later attributed to increased gastric and colonic transit, possibly caused by activation of FGFR's on enteric neurons [88] . NGM282 treatment in PSC is being evaluated, but no data has been published yet. The current studies performed have all been conducted over a short term of 4-12 weeks and follow up studies will be needed to see whether NGM282 has beneficial effects on long term outcome parameters such as liver transplant-free survival.
Interruption of hepatic or intestinal bile salt (re)uptake
Interruption of the enterohepatic circulation of bile acids by targeting hepatic or intestinal bile salt (re)uptake and thereby reducing the bile salt load on hepatocytes is also under development as treatment strategy for cholestasis. Inhibiting the intestinal bile salt transporter ASBT reduced cholestatic liver injury in Mdr2-deficient mice, by stimulating loss of bile salts in the feces [89, 90] . Two different ASBT inhibitors have been tested in clinical trials so far, namely A4250 (or LUM001) and GSK2330672. Both drugs did not affect biomarkers of cholestatic liver injury, but clearly reduced pruritus in patients with PBC [91, 92] . Unfortunately, a major drawback of ASBT inhibitors is the occurrence of bile acid-induced diarrhea, which was experienced by a large majority of patients [91, 92] . Of further concern are the reports of increased tumor formation in the colon of ASBT-and FGF15-deficient mice, which has been suggested to be associated with the high fecal bile salt levels [93, 94] . These side effects are likely to affect treatment adherence or limit the long-term use of ASBT-inhibitors in clinical settings [95] . More recently, it was shown that inhibition of hepatic bile salt uptake, by blocking NTCP, effectively reduced cholestatic liver injury in several cholestatic models in mice. Mechanistically, NTCP inhibition by the drug Myrcludex B reduced bile salt load on hepatocytes and increased the phospholipid to bile salt ratio, rendering the bile less toxic [96] . The reduction in bile salt accumulation in hepatocytes likely also contributed to the attenuated inflammation in these models [68] . cholestasis has not yet been performed.
Non-alcoholic fatty liver disease and steatohepatitis (NAFLD and NASH)
NAFLD is defined by the accumulation of triglycerides in the liver and this condition is tightly linked to the metabolic syndrome and associated with features such as insulin resistance, type 2 diabetes (T2D), hypertension and (visceral) obesity [97] . NASH, affecting 15% of the NAFLD patients, is an advanced condition of NAFLD in which the liver is fibrotic and inflamed with an increased risk of developing cirrhosis and hepatocellular carcinoma [98, 99] . On top of that, NAFLD patients experience increased risk of cardiovascular disease [100] . To date liver transplantation is the only curative treatment for cirrhotic NASH patients and drugs that halt progression of NASH are urgently needed.
Targeting the FXR-FGF19 pathway
Of the two most well described bile acid receptors, FXR is currently considered to be the most promising candidate for the treatment of NAFLD and NASH. The FXR agonists OCA and WAT-362450 reduced hepatic steatosis in animal models of the metabolic syndrome [101] [102] [103] and attenuated liver inflammation and fibrosis in MCD-induced NASH [104] . OCA treatment also reduced body weight gain and adiposity, and improved glucose levels and tolerance in these studies.
The first randomized placebo-controlled clinical trial reported a good safety profile, increased insulin sensitivity, and reduced markers of inflammation and fibrosis in NAFLD and T2D patients treated with OCA [105] . Long-term effects of OCA treatment on NASH were investigated in the FLINT trial (NCT01265498) in which NASH patients were administered 25 mg of OCA (or placebo) daily for 72 weeks. Of the OCA-treated patients 45% improved their NAFLD activity score, assessed by liver biopsies, and OCA treatment was associated with weight loss [106, 107] . However, in contrast to the first study in NALFD and T2D patients, treatment with OCA increased fasting insulin concentrations and the homeostasis model of assessment of insulin resistance (HOMA-IR) score in NASH patients [106] . Of additional concern was the increase in LDL-cholesterol. After discontinuation of OCA treatment the cholesterol levels, and also insulin and HOMA-IR levels, reverted towards baseline. Similarly the improvements observed in liver enzymes were not sustained after the treatment period. Adverse events were mild in both clinical trials, except for the side effect of pruritus, which occurred in 23% of OCA-treated patients [106] . Dose-adaptations and treatment optimization might overcome the drawbacks of pruritus, increased LDL cholesterol and decreased insulin sensitivity. Currently, two phase 3 clinical trials are ongoing, the REGENERATE trial (NCT02548351) investigates the effects of OCA on NASH associated fibrosis and the REVERSE trial (NCT03439254) investigates the effects of OCA in NASH patients with compensated cirrhosis. Results are expected in the coming years.
The FXR agonists LJN452 and GS-9674 are also evaluated for their effectiveness in NASH patients. LJN452 is being tested in NASH patients in a phase 2 trial (NCT02855164), but no results have been reported 
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Biochemical Pharmacology 161 (2019) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] yet. The compound GS-9674 is being tested (either alone, as part of combinational therapy with an inhibitor of apoptosis signal-regulating kinase 1 (ASK1) and/or an inhibitor of Acyl-CoA carboxylase (ACC)) in several different NASH populations in phase 2 trials (NCT02854605, NCT03449446, NCT02781584). Thus far Gilead reported that liver biochemistry and markers of fibrosis improved with the combinational treatment of its compound GS-9674 and the ASK1 inhibitor, but the data has not been published yet (13th of april 2018, Gilead press release). Furthermore, the FGF19 mimetic NGM282 is of interest in the field of fatty liver disease. Currently, NGM282 is being evaluated as a treatment for NASH in a phase 2 trial (NCT02443116), after anti-inflammatory, anti-steatotic and anti-fibrotic effects of NGM282 were reported in a murine NASH model [108] . First results of the phase 2 clinical trial report that 76% of patients that received NGM282 met the primary endpoint of a 5% reduction in liver fat content after 12 weeks of therapy [109] . Similar to the trials of NGM282 in PBC diarrhoea, abdominal pain and nausea were reported for 38%, 24% and 24% respectively in patients treated with NGM282. Long term effectiveness of NGM282 in NASH patients is currently being evaluated.
TGR5 agonists
Unlike FXR agonists the use of TGR5 agonists in the NAFLD/NASH field is limited to animal experiments. The TGR5 agonist INT-777 did reduce hepatic steatosis and adiposity in obese mice [61] , but no clinical follow up has been realized.
Reducing intestinal bile acid uptake
Strategies modulating bile acid transport might also develop into effective NAFLD and NASH treatments. First of all, bile acid sequestrants shield bile salts from efficient uptake in the intestine and as such stimulate bile salt loss via the faeces. To compensate for the loss of bile acids, de novo bile acid synthesis is increased and thus more cholesterol is catabolized, thereby successfully decreasing plasma cholesterol levels [110] . Only a hand-full of studies investigated the effect of bile acid sequestrants on NAFLD and NASH and they actually indicate that bile acid sequestrants are not effective or even disadvantageous in these conditions. For example, in Ob/Ob mice the bile acid sequestrant cholestyramine did not have any effect on hepatic triglyceride content and even increased ALAT levels, a biochemical marker of hepatocellular injury [111] . In accordance, one study that specifically evaluated the effect of bile acid sequestrants in NASH patients reported a negative effect of sequestrants on liver fat content [112] . The exact mechanism underlying these observations is not known, but it has been shown that bile acid sequestrants can stimulate de novo lipogenesis [113] , which is unwanted in steatotic livers. These results clearly argue against the use of bile acid sequestrants for the treatment of NAFLD or NASH.
Similar to bile acid sequestrants, inhibitors of bile acid (re)absorption in the intestine, ASBT inhibitors, also stimulate de novo bile salt synthesis, which induces turnover of cholesterol. In animal models it has been demonstrated that ASBT-deficiency and the ASBT-inhibitor SC-435 reduced hepatic lipid accumulation and plasma cholesterol levels [114, 115] . In humans the use of the ASBT-inhibitors volixibat or elobixibat reduced plasma cholesterol levels in healthy volunteers and overweight, obese, constipated and T2D patients [116] [117] [118] . Importantly, the use of the ASBT-inhibitor volixibat was well tolerated [116] , and at the moment the effect of volixibat on the histological NAFLD activity score is being evaluated in a phase 2 trial (NCT02787304). Overall, ASBT-inhibitors appear more promising than bile acid sequestrant therapy for NASH, indicating that ASBT-inhibition has additional protective effects in the context of NASH besides the loss of bile salts via the faeces and increased turnover of cholesterol. Possibly this is related to the fact that ASBT-inhibition does not dampen intraluminal signalling by bile salts to the same extent as bile acid sequestrants, which shield the bile salts in complexes thereby restricting exposure of bile salts to receptors such as TGR5 in the gut.
Atherosclerosis
Atherosclerosis is a disease caused by both imbalanced lipid metabolism and a chronic inflammatory state. These processes can both be targeted by bile salt signalling and it is therefore not surprising that many pre-clinical studies have evaluated the effects of FXR agonists, TGR5 agonists and ASBT inhibitors on atherosclerotic development.
FXR agonists
FXR has many potential beneficial effects in the context of atherosclerosis, but at the moment it is uncertain whether FXR agonists are suitable for the treatment of atherosclerosis. Three mice studies report on the consequence of loss of FXR in atherosclerosis susceptible mice models, and did not provide consistent results [119] [120] [121] . One study reported aggravated atherosclerosis development in FXR/ApoE double KO mice [119] , whereas two other studies reported that loss of FXR in low density lipoprotein receptor (LDLR)-deficient mice and ApoE-deficient mice reduced atherosclerotic lesion size [120, 121] . The exact cause of these discrepancies remains uncertain, but gender differences in the mice models used might play a role. In contrast, FXR stimulation with the FXR agonists PX20606 or WAY-362450 did prevent atherosclerotic plaque formation in ApoE KO, LDLR KO or CETP tg LDLR KO models [122, 123] . Although in the study with PX20606 only male mice were used, in the study with the WAY-362450 compound reduction of atherosclerosis was observed in both male and female mice, indicating that FXR agonism effectively reduces atherosclerosis irrespective of gender [122, 123] . The beneficial effects of FXR stimulation are attributed to improvements in the lipid profile in a SHP dependent manner. It has to be stated that the SHP dependent effect was gender specific for female mice as SHP deficient male mice still showed reduction of plasma lipids upon FXR activation [122] . Additionally, FXR stimulation modulates inflammatory responses thereby reducing pro-inflammatory cytokine production [123] . Unfortunately, the reported increase in LDLcholesterol and decrease in HDL-cholesterol in OCA treated patients [105] , makes FXR agonists a less attractive option to treat atherosclerosis in humans and has likely restrained the initiation of any clinical trials.
TGR5 agonists
The immunomodulatory functions of TGR5 on macrophages make this GPCR an interesting target in the setting of atherosclerosis [67] . The studies on the effects of specific TGR5 agonists and on atherosclerotic development are however limited to animal models. The most extensively studied TGR5 agonist, INT-777, was shown to reduce atherosclerosis development in LDLR KO mice. This result was critically dependent on the presence of TGR5 in bone marrow derived cells, as INT-777 treatment of LDLR KO mice transplanted with TGR5-deficient bone marrow did not reduce atherosclerotic plaque size. TGR5 activation on macrophages reduced production of pro-inflammatory cytokines and decreased lipid uptake by the macrophages [64] . The later reported inhibitory effects of TGR5 on the NLRP3 inflammasome. This likely contributed to the decrease in atherosclerotic plaque formation [67] , since inflammasome activation is a major driver of atherosclerosis development. It has also been reported that oleanolic acid (OA), a triterpenoid that can activate TGR5 [124] , had anti-hyperlipidemic and anti-atherosclerotic effects in several rabbit and mouse models [125, 126] . In a clinical trial profound lipid-lowering effects were reported after four weeks daily administration with OA [127] . It is however far from certain that the reduction in plasma lipids is mediated via TGR5, since OA also stimulates other receptors and cholesterol lowering was not induced by TGR5 activation in mice studies [64] .
Reducing intestinal bile acid uptake
As hypercholesterolemia is a major risk factor of atherosclerosis, it was deemed worthwhile to investigate the effects of ASBT-inhibition or bile acid sequestrants on atherosclerotic development. In fact, bile acid sequestrants (such as colesevelam and colestimide) were originally developed as a treatment for hypercholesterolemia. In clinical trials in the early 1980s bile acid sequestrants were critical in showing that lowering of LDL-C provided protection against future cardiovascular events in hypercholesteremic patients [128] . Sequestrants, however do have one major downside, they increase colonic transit time, thereby increasing the risk of constipation [129] . Since the development of statins, sequestrants are no longer used as first line treatment for hypercholesterolemia.
Where bile acid sequestrants have been around for decades, ASBTinhibitors have only made their way to the clinic recently. It was shown that ASBT deficiency in ApoE KO mice protected against atherosclerotic development, by lowering plasma cholesterol levels [130] . Similarly, treatment with the ASBT-inhibitor SC-435, alone and in combination with a statin, reduced atherosclerosis development in guinea pigs [115] . A clinical trial investigating the effects of ASBT-inhibitors on atherosclerosis has however not been undertaken. Nevertheless, results from trials focusing on resolution of constipation by treatment with ASBT-inhibitors do indicate that ASBT-inhibitors lower plasma cholesterol [116, 118] providing a rationale for future studies focusing on hypercholesterolemia. Of note, in any future studies careful monitoring of patients is warranted, due to the reports of increased colonic neoplasia in mice with continuous high bile salt levels in the feces [93, 94] .
Type 2 diabetes
T2D is characterized by deregulated glycemic control and systemic insulin resistance. It is estimated that approximately 150 million people suffer from T2D worldwide. Major complications of T2D are cardiovascular disease, retinopathy, neuropathy and nephropathy. Below we discuss the role of bile acids in regulating the glycemic response raising the interest for bile acid based therapies. Most of the effects of bile salts on glucose homeostasis are attributed to TGR5 activation, but also inactivation of specifically intestinal-FXR may contribute to glycemic control.
The ambivalent role of FXR
The discrepant role of FXR activation on glucose homeostasis make it a disputable target for the treatment of T2D. The use of the FXR agonist OCA in NAFLD and T2D patients initially provided positive results, as insulin sensitivity was increased [105] . However, the negative results of the FLINT trial on increased fasting insulin concentrations and higher HOMA-IR score [106] , indicate that FXR activation is not the most suitable treatment for T2D. Most of the present data actually indicates that an intestinal FXR-antagonist might prove more worthwhile to improve glycemic control, although no translation into human trials have been made so far. For example, tauro-β-muricholic acid and its derivative Gly-MCA have competitive inhibitory effects on FXR in rodents and were demonstrated to improve glucose tolerance and insulin sensitivity [48, 131, 132] . Mechanistically the inhibition of intestinal-FXR was suggested to reduce ceramide synthesis, which subsequently led to reduced mitochondrial acetyl-CoA levels and pyruvate carboxylase activity attenuating hepatic glucose production [132] .
Synthetic and natural TGR5 agonists
The role of TGR5 in glucose metabolism, energy expenditure and inflammation renders it a potential therapeutic target for the metabolic syndrome and T2D, which stimulated the development and patented registration of hundreds of selective TGR5 agonists [133] . Especially the compound INT-777 has been studied extensively with remarkable in vivo effects on GLP-1 secretion, glycemic control, energy expenditure, and adiposity thereby attenuating obesity and T2D in mice [61, 134] . However, to date only one selective TGR5 agonist has been tested in a clinical trial, executed almost 10 years ago (NCT00733577). In this study the compound SB-756050, was administered daily to subjects with T2D for 6 days [135] . Based on earlier results in (diabetic) rats and dogs, dose-dependent increases on GLP-1 and peptide YY (PYY) were expected, consequently resulting in an overall improvement of the glucose profiles of the subjects. In contrast, subjects administered with the two lowest doses of 15 and 50 mg SB-756050 had increased fasting glucose levels and higher glucose levels during an oral glucose tolerance test (OGTT). Subjects administered with the high doses of 100 and 200 mg did not show any changes on glucose levels and OGTT performance. GLP-1 and PYY levels were only changed at the higher doses, potentially via activation of the L-cells in the distal ileum and colon by the unabsorbed part of the drug. No adverse events were reported, but the high variability of the study outcomes and activation site of the drug needs further investigation.
The plant-derived triterpenoid OA, which was reported to be a TGR5 agonist, improved glycemic control in obese mice [124] and attenuated plasma triglycerides in hyperlipidemic patients [127] . However, the triterpenoids are not selective TGR5 agonists, which warrants careful interpretation of these studies.
The question rises why clinical application of TGR5 targeted therapy has thus far not been realized, despite abundant positive reports of pharmacological TGR5 activation in rodents. The reason for this restraint are several major drawbacks considered to be associated with TGR5 activation, namely increased gallstone formation, pruritus, cardiovascular side effects and tumorigenesis. Genetic deletion of TGR5 has been reported to protect mice against gallstones [36] and pancreatitis [136] , whilst administration of TGR5 agonists has been demonstrated to stimulate gallbladder filling, likely caused by TGR5-dependent relaxation of smooth muscle cells [137] . It is uncertain whether TGR5 stimulation directly predisposes to cholesterol gallstone formation, but decreased gallbladder motility has been associated with the presence of gallstones [7] . Bile acid-induced pruritus has also been linked to TGR5, as was shown by itch and analgesia transmitter release by mouse dorsal route ganglia and spinal cord neurons in response to bile acids and a TGR5-selective agonist, as well as by increased scratching and spontaneous pruritus in TGR5 transgenic mice [138] . Furthermore, one study reported on a prominent reduction in blood pressure and reflex tachycardia in dogs after infusion with several different TGR5 agonists, likely caused by TGR5 activation in endothelial cells [139] . The final major drawback of TGR5 agonism might be the controversial role of TGR5 in proliferation and tumorigenesis. In both in vitro and in vivo models it was shown that TGR5 plays a key role in cholangiocyte proliferation and inhibition of apoptosis, thereby increasing the risk of cholangiocarcinoma [140] . Furthermore, TGR5 expression has been linked to esophageal adenocarcinoma in patients [141] and in vitro studies demonstrated increased growth rates of both esophageal adenocarcinoma cells and gastric cancer cells upon TGR5 activation [142, 143] . Although most deleterious effects associated with TGR5 have been observed in vitro or in animal studies, and therefore might not accurately predict the effects in humans, the predicted risks presumably influences the slow transition of selective TGR5 agonists towards clinical practice.
Instead of synthetic TGR5 agonists bile salts themselves have been employed to stimulate GLP-1 release via TGR5 activation. Several clinical trials have been executed with the bile salts ursodeoxycholic acid (UDCA), CDCA, and taurocholic acid (TCA) (NCT01337440, NCT01666223). UDCA treatment for 12 weeks augmented the sitagliptin-induced boost of GLP-1 secretion and reduced body weight and HbA1c levels in T2D patients [144] . Rectal infusion of TCA promptly stimulated GLP-1 and PYY secretion [145] , and intragastric infusion of CDCA increased GLP-1 and glucagon levels [146] . Both CDCA and UDCA stimulated GLP-1 release in patients after bariatric surgery [147] .
The ability of bile acids to increase energy expenditure in brown adipose tissue via TGR5 activation [60] is also emerging as potential therapeutic target. Preclinically, both CA and CDCA feeding reversed obesity via TGR5-mediated enhanced energy expenditure in brown adipose tissue [60, 148] . In humans, CDCA treatment of healthy volunteers for 2 days increased brown adipose tissue activity which resulted in increased whole-body energy expenditure [149] . Although it might be discussed if these study results can selectively be ascribed to TGR5 agonism alone, especially CDCA is in fact a stronger FXR agonist, these studies do highlight the potential of bile acid based therapies as treatment of the metabolic syndrome and T2D.
ASBT inhibitors and bile acid sequestrants
As bile acid sequestrants were found to lower plasma glucose concentrations and improve glycemic control in T2D patients [150] , the ability of bile acid sequestrants and ASBT inhibitors to prevent bile acid uptake in the intestine is suggested as treatment strategy for T2D. The exact mechanism is likely dependent on increased TGR5 activation by bile acids retained in the colon [151] . Sequestrant therapy also alters the ratio of CA to (C)DCA and renders the bile salt pool more hydrophilic, which could further alter the signaling effects on both FXR and TGR5 [152] . Additionally it has been reported that sequestrants increase colonic transit time [129] , allowing increased bacterial dehydroxylation and thus increasing the amount of deoxycholic acid, a potent TGR5 agonist likely to activate the intestinal L-cells to secrete GLP-1. Indeed, GLP-1 secretion is increased in response to sequestrants in T2D patients [152] . The prolonged colonic transit time also has a negative annotation as it leads to constipation, which is noted as the main side effect of sequestrants [129, 150] . Nevertheless, the number of clinical trials completed and ongoing with sequestrants in T2D patients reflects a potential new field of application for this class of drugs.
ASBT inhibitors also reduce the reabsorption of bile acids and potentially increase the chance of intestinal L-cell TGR5-signaling to stimulate GLP-1 secretion. Reports of ASBT inhibitors leading to an increase in GLP-1 secretion have not been consistent. For instance, SC-435 failed to increase GLP-1 secretion [153] while on the other hand 264 W94 did increase GLP-1 levels and improve glycemic control [154] . Of note, both studies were performed in diabetic rat models. Nevertheless, human data on the ASBT inhibitor Elobixibat (or A3309) are encouraging since several clinical trials confirm increased GLP-1 levels after treatment [155] (NCT01069783 and NCT01038687).
Inflammatory bowel disease
The prevalence of inflammatory bowel disease (IBD), specifically ulcerative colitis and Crohn's disease, has increased greatly over the past decades. The exact etiology of IBD remains largely unknown and treatment has focused on controlling inflammation. A pathogenic role for bile acids in IBD has previously been suggested, however recent studies have shown that modulation of bile salt signaling may actually be beneficial in the context of IBD.
FXR agonists
The role of FXR activation in the intestine extends beyond the control of bile salt synthesis and bile salt reuptake from the gut. Bile salt deficiency in the intestine, by obstruction of the bile duct, is associated with mucosal injury and bacterial overgrowth and translocation, but could be restored by administration of bile salts or the FXR agonist GW4064 [156, 157] . Following these results it was demonstrated that FXR activation with OCA decreased the severity of dextran sodium sulfate (DSS) and trinitrobenzenesulfonic acid (TNBS) induced colitis in mice, by maintenance of epithelial barrier function and inhibiting proinflammatory cytokine production by directly acting on immune cells, suggesting that pharmacological FXR activation has therapeutic potential for IBD [158, 159] . To date no clinical trials have started investigating the effect of FXR agonists in IBD, likely related to the fact that for IBD an intestine-or immune cell-specific FXR agonist might be more beneficial because this is the desired site of action [160] .
TGR5 agonists
Early reports on the function of TGR5 suggested that it has a protective role in the intestine by attenuating inflammatory processes. TGR5 KO mice have increased intestinal permeability compared to wild type mice [161] . In addition it was shown that the TGR5 agonist 3-Aryl-4-isoxazolecarboxamide could reduce cytokine production by mononuclear cells isolated from the lamina propria of Crohn's disease patients [66] . Moreover, BAR501 a small molecule agonist for TGR5, protected mice against TNBS and oxazolone induced colitis. In this model the effect of BAR501 was critically dependent on a IL-10 dependent phenotype shift of activated macrophages [162] . It has also been reported that TGR5-activating triterpenoids, OA and betulinic acid have regulatory effects on chemically induced colitis. Betulinic acid ameliorated DSS-induced colitis [163] while OA attenuated TNBS-induced colitis [161] . However, it has to be noted that the immunosuppressive effects of betulinic and OA in those studies have not been shown to be critically dependent on TGR5 [161, 163] . BIX02694, another TGR5 agonist, attenuated dinitrobenzenesulfonic acid (DNBS)-induced colitis in rats [139] . Overall, sufficient preclinical evidence exists that TGR5 activation could be beneficial in treating IBD, but the side effects associated with TGR5 agonists likely prevented clinical evaluation.
Challenges and future perspectives of bile salt based therapies
Although multiple bile salt based therapeutics are under investigation in clinical trials, a number of challenges still persist before broad clinical adaptation is likely to be realized. First of all, to limit the side effects of systemic acting FXR and TGR5 agonists, development of compounds that stimulate signaling in a tissue specific manner seems pivotal. The intestinal specific FXR agonist fexaramine is an example of such a drug [51] . More recently, three intestinal selective TGR5 agonists have been produced: compound 15c [164] , compound 24 [165] , and compound 26a [166] . So far it has been demonstrated that these compounds have limited effects on gallbladder filling but retain their effects on GLP-1 secretion and glucose regulation [164] [165] [166] .
Besides tissue specific agonists, combining treatments might enhance treatment efficacy and allow for lower dosing, limiting dosedependent side effects. Previously, we proposed the use of ASBT inhibitors combined with FXR agonists for the treatment of PSC [95] . Such drug combinations may also be useful for other cholestatic diseases or NAFLD/NASH. Alternatively, a dual agonist for TGR5 and FXR, INT-767, has been designed and seems to merge all positive effects of FXR and TGR5 activation. INT-767 treatment increases GLP-1 secretion, improves glycemic control, reduces cholesterol and triglyceride plasma levels, and improves hepatic steatosis and inflammation in obese and diabetic mice [167, 168] . Furthermore, liver injury was reduced in a murine model of cholestasis [169] and INT-767 reduced atherosclerotic plaque formation and inflammation in mice [170] . Despite the remaining questions about detailed mechanistic actions of INT-767 and the concerns about systemic TGR5 agonism, the developer Intercept Pharmaceuticals announced a phase I clinical trial in 2015. However, thus far it does not seem that the trial has actually been initiated.
Finally, bile acids themselves, the endogenous activators of TGR5 and FXR, are not to be forgotten when considering new treatment strategies. Administration of bile salts has been documented to stimulate TGR5 dependent effects such as GLP1 release and increased brown adipose tissue activity [146, 149] . Instead of administration of bile salts directly, the concept of inhibiting hepatic bile acid uptake may also lead to an increase in systemic bile salt levels [10, 12] . Inhibition of NTCP by Myrcludex B temporarily increases systemic bile acid levels up to 200 µM in humans [171] . These high concentrations of endogenous bile salts potentially induce a cascade of signaling events, which may have beneficial metabolic effects useful for the treatment of the metabolic syndrome and associated diseases. Additionally, the diminished uptake of bile salts by hepatocytes has already been shown to reduce the bile salt load on the liver in cholestatic conditions, reducing cholestatic liver injury [96] . The first steps towards clinical application of NTCP inhibition have already been undertaken, as Myrcludex B has been tested in hepatitis B and δ co-infected patients [172] . The drug was well tolerated and no adverse events were reported in studies with daily treatment of Myrcludex B for up to 24 weeks. The safety and tolerability of this drug makes Myrcludex B an interesting candidate to start clinical trials to investigate its effect on metabolic diseases.
Conclusion
Pre-clinical studies on the effects of bile salt based therapies have provided hope regarding the potential of these strategies to treat metabolic and inflammatory diseases. At the moment several drugs have advanced to evaluation in clinical trials. These developments are promising, but one does need to realize that clinical application is in its early stages as long term effectiveness of these therapies still needs to be established using clinically relevant outcome parameters such as prolonged life expectancy or delaying the need for liver transplantation. Additionally, in some cases the promise of pre-clinical studies is hampered by the side effects reported in animal experiments. Therefore, to improve translation from the promising pre-clinical stage towards application in humans new developments are still required.
